Investor Materials

Transforming the treatment of
B cell-mediated autoimmune diseases


annual report

View the below digital version of our Annual Report.


proxy statement

View the below digital version of our Proxy Statement.


request paper materials

You may request paper copies of the proxy materials by
phone, email or online.  Phone: 866-648-8133

vote now

Your vote is IMPORTANT! You may vote online or by phone.
To vote by phone, dial 866-256-1193.


June 2, 2020


10:00 AM EDT

Virtual Meeting

To Register for the Meeting

Deadline to Register*

May 29, 2020
5:00 PM EDT

*Note: You must register by the deadline to be eligible to participate in the meeting.

About Us

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Our proprietary technology utilizes chimeric autoantibody receptor, or CAAR, T cells that are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies (pathogenic B cells) while sparing normal B cells. Our lead CAAR T cell product candidate was designed based on chimeric antigen receptor, or CAR, T cell technology that has been successfully developed and is marketed for the treatment of B cell cancers. Our technology, in combination with our proprietary Cabaletta Approach for selective B cell Ablation platform, called our CABA platform, has applicability across more than two dozen B cell-mediated autoimmune diseases that we have identified, reviewed and prioritized. During the past two years, using our CABA platform, we have discovered and developed four product candidates, including our lead product candidate, in development to treat patients with mucosal pemphigus vulgaris, or mPV, and three additional product candidates that have demonstrated specific and selective target engagement in vitro.